Copyright
©2013 Baishideng Publishing Group Co.
World J Obstet Gynecol. Nov 10, 2013; 2(4): 153-166
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.153
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.153
Study | n | PDS (n) | Optimal surgery1 | Criteria of residual diseases (cm) | Sensitivity | Specificity | PPV | NPV | Accuracy |
Angioli et al[71], 2006 | 87 | 53 | 96% | 0 | - | - | - | - | - |
Deffieux et al[72], 2006 | 15 | 11 | 91% | 0 | - | - | - | - | - |
Fagotti et al[73], 20062 | 64 | 61 | 67% | 1 | 30% | 100% | 100% | 70% | 74% |
Fagotti et al[74], 20082 | 113 | 91 | 50% | 1 | 30% | 100% | 100% | 60% | 75% |
Brun et al[75], 20082 | 55 | 26 | 69% | 1 | 46% | 89% | 89% | 44% | 60% |
- Citation: Tangjitgamol S, Hanprasertpong J, Cubelli M, Zamagni C. Neoadjuvant chemotherapy and cytoreductive surgery in epithelial ovarian cancer. World J Obstet Gynecol 2013; 2(4): 153-166
- URL: https://www.wjgnet.com/2218-6220/full/v2/i4/153.htm
- DOI: https://dx.doi.org/10.5317/wjog.v2.i4.153